Related Experiment Videos
[Exploratory study of macromomycin]
Abstract:
Macromomycin, a new antitumor antibiotic (NSC-170105) with significant antitumor activity in animal tumor systems, was administered to 18 patients in an exploratory study. The dose ranged from 1mg to 30 mg per body with a single dose was given. The toxic effects included delayed type leukopenia and thrombocytopenia with nadir of 4 weeks. Except mild upper GI disturbance, no pulmonary, cardiac, hepatic, renal or CNS toxicity was observed. No anaphylaxis was observed in this study. MTD of macromomycin considered to be 26 mg/m2 and optimal administration schedule will be 20 mg/m2 every 6 weeks. Antitumor activity was detected in one patient with ovarian carcinoma with MR in short period.
Insights
Macromomycin, an antitumor antibiotic, showed potential in a patient study, with toxic effects like leukopenia observed. The maximum tolerated dose (MTD) was determined, suggesting an optimal administration schedule for future research.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Macromomycin is a novel antitumor antibiotic demonstrating efficacy in preclinical animal models.
- Exploratory studies are crucial for evaluating the safety and potential of new chemotherapeutic agents.
Purpose of the Study:
- To assess the safety and tolerability of macromomycin in cancer patients.
- To determine the maximum tolerated dose (MTD) and optimal administration schedule for macromomycin.
- To evaluate preliminary antitumor activity of macromomycin.
Main Methods:
- An exploratory study involving 18 patients administered single doses of macromomycin ranging from 1 mg to 30 mg.
- Monitoring for toxic effects, including hematological, pulmonary, cardiac, hepatic, renal, and central nervous system toxicity.
- Evaluation of antitumor responses.
Main Results:
- Delayed leukopenia and thrombocytopenia were the primary toxic effects, with a nadir at 4 weeks.
- Mild gastrointestinal disturbances were noted; however, no significant pulmonary, cardiac, hepatic, renal, or CNS toxicity was observed.
- Macromomycin was generally well-tolerated, with no anaphylaxis reported. The MTD was estimated at 26 mg/m2.
- Preliminary antitumor activity was observed in one patient with ovarian carcinoma, showing a minor response (MR).
Conclusions:
- Macromomycin exhibits a manageable toxicity profile, with hematological effects being dose-limiting.
- An optimal administration schedule of 20 mg/m2 every 6 weeks is proposed based on MTD findings.
- Further clinical trials are warranted to confirm the efficacy and refine the use of macromomycin in cancer treatment.